Related Experiment Video
Updated: Aug 11, 2026
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and
Sonia Messina1, Domenica Altavilla, M'hammed Aguennouz
1Department of Neuroscience, Psychiatry, and Anaesthesiology, University of Messina, Messina, Italy.
Abstract:
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease resulting from lack of the sarcolemmal protein dystrophin. However, the mechanism leading to the final disease status is not fully understood. Several lines of evidence suggest a role for nuclear factor (NF)-kappaB in muscle degeneration as well as regeneration in DMD patients and mdx mice. We investigated the effects of blocking NF-kappaB by inhibition of oxidative stress/lipid peroxidation on the dystrophic process in mdx mice. Five-week-old mdx mice received three times a week for 5 weeks either IRFI-042 (20 mg/kg), a strong antioxidant and lipid peroxidation inhibitor, or its vehicle. IRFI-042 treatment increased forelimb strength (+22%, P < 0.05) and strength normalized to weight (+23%, P < 0.05) and decreased fatigue (-45%, P < 0.05). It also reduced serum creatine kinase levels (P < 0.01) and reduced muscle-conjugated diene content and augmented muscle-reduced glutathione (P < 0.01). IRFI-042 blunted NF-kappaB DNA-binding activity and tumor necrosis factor-alpha expression in the dystrophic muscles (P < 0.01), reducing muscle necrosis (P < 0.01) and enhancing regeneration (P < 0.05). Our data suggest that oxidative stress/lipid peroxidation represents one of the mechanisms activating NF-kappaB and the consequent pathogenetic cascade in mdx muscles. Most importantly, these new findings may have clinical implications for the pharmacological treatment of patients with DMD.
Insights
This study shows that inhibiting oxidative stress with IRFI-042 improves muscle strength and reduces damage in Duchenne muscular dystrophy (DMD) mouse models by blocking NF-kappaB activation.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration.
- The precise mechanisms driving DMD pathology, particularly the role of inflammation and oxidative stress, are not fully elucidated.
- Nuclear factor-kappaB (NF-kappaB) has been implicated in both muscle degeneration and regeneration processes in DMD.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting oxidative stress and lipid peroxidation on the dystrophic process in mdx mice, a model for DMD.
- To determine if blocking oxidative stress can modulate NF-kappaB activation in dystrophic muscles.
Main Methods:
- Administration of IRFI-042, an antioxidant and lipid peroxidation inhibitor, or vehicle to 5-week-old mdx mice for 5 weeks.
- Assessment of muscle strength, fatigue, serum creatine kinase levels, and markers of oxidative stress (conjugated dienes, reduced glutathione).
- Evaluation of NF-kappaB DNA-binding activity and tumor necrosis factor-alpha expression in muscle tissue.
Main Results:
- IRFI-042 treatment significantly improved forelimb strength and reduced fatigue in mdx mice.
- Treatment decreased markers of muscle damage (creatine kinase, conjugated dienes) and oxidative stress, while increasing antioxidant capacity (reduced glutathione).
- IRFI-042 inhibited NF-kappaB activation and reduced pro-inflammatory cytokine expression, leading to decreased muscle necrosis and enhanced regeneration.
Conclusions:
- Oxidative stress and lipid peroxidation are key mechanisms that activate NF-kappaB in DMD, contributing to muscle pathology.
- Inhibition of oxidative stress via IRFI-042 demonstrates a promising therapeutic strategy for DMD by modulating inflammatory pathways.
- These findings suggest potential clinical applications for antioxidant therapies in managing Duchenne muscular dystrophy.
